Jacques R. Essinger

Directeur Général chez

Polares Medical SA

Health Technology

Finance

Consumer Services

Profil

Jacques R.
Essinger is the founder of Diagnoplex SA, founded in 2005.
Current jobs include Chairman & Chief Executive Officer at Polares Medical SA since 2017, Chairman & Chief Executive Officer at Polares Medical, Inc. since 2017, Director at Nuvaira, Inc., Director at V-Wave Ltd., and Operating Partner at Endeavour Vision SA since 2017.
Former jobs include Chief Executive Officer & Director at Symetis SA, Director at DFB Pharmaceuticals LLC, Director at Vexim SA, Director at Polytech Advisors SA, Member-Management Board at Genedata AG, and Venture Partner at Aravis AG from 2002 to 2013.
Education includes a doctorate from École Polytechnique Fédérale de Lausanne.

Postes actifs de Jacques R. Essinger

Sociétés	Poste	Début
Endeavour Vision SA Endeavour Vision SA Investment ManagersFinance EV develops a long-term investment strategy with their entrepreneurs. Their investment objective is to grow firms and to create a market leader in a new field. They focus on developing businesses active in industries including information technology, biotech, medtech and cleantech. They concentrate on various stages such as early to expansion-stage as well as spin-offs and restarts. Their geographic focus is pan-European. Specifically, their technology-sector investments are concentrated in Norway, Sweden, Finland, UK, Ireland, Germany, Switzerland, France, Italy and Portugal. Beyond these countries, they also consider taking a co-lead or a syndicate role. For their life sciences investments, they primarily target Switzerland, France and Germany. Four key investment criteria they consider before investment are hyper-growth market potential, world-class technology, capital efficiency and ambitious management team. EV's preferred role is to be lead investor or possibly co-lead. They also consider being syndicate partner on some occasions. EV's investment horizon is generally 10 years, with that timeframe extended for firms in hyper-growth stage. On average, their investments typically take five years to mature. The majority of their exits are through a listing in one of the main markets while many of the VC-backed firms are acquired.	Private Equity Investor	01/01/2017
V-Wave Ltd. V-Wave Ltd. Medical SpecialtiesHealth Technology Develops treatment options for people living with heart failure and cardiovascular disease	Directeur/Membre du Conseil	-
Polares Medical SA Polares Medical SA Medical SpecialtiesHealth Technology Operates as a medical device company with a novel devices for treating mitral valve regurgitation	Directeur Général	01/06/2017
Nuvaira, Inc. Nuvaira, Inc. Medical SpecialtiesHealth Technology Develops medical devices for treating lung diseases	Directeur/Membre du Conseil	-
Polares Medical, Inc. Polares Medical, Inc. Part of Polares Medical SA, Polares Medical, Inc. is an American medical device company focused on developing a novel device to treat mitral valve regurgitation. The company is located in the US.	Directeur Général	01/06/2017

Tous les postes actifs de Jacques R. Essinger

Anciens postes connus de Jacques R. Essinger

Sociétés	Poste	Fin
Aravis AG Aravis AG Investment ManagersFinance Aravis is a hands-on investment partner. They work closely with their portfolio firms while providing capital and access to their international network of professionals. The firm's investment strategy targets early-stage firms active in biopharmaceutical, medical technology and biotechnology sectors in Europe, North America and Asia. They have a particular focus on cross-border deals and in firms operating in immunology, inflammation, oncology and CNS segments. They also invest in renewable energy businesses in Europe where they believe there are substantial growth opportunities. They concentrate on firms in the development phase which employ mature established energy production technologies, namely wind, hydroelectric or photovoltaic cells. Aravis has experience initiating, financing and structuring complex projects. The firm aims to diligently conduct scientific and technical analysis of potential projects prior to capital commitment. They look for firms which display optimal risk/return profiles. They closely monitor the quality of the science and actively continue with hands-on intervention in challenging situations, aiming to create value through deal structuring in parallel with careful entry valuations.	Private Equity Investor	31/12/2013
Polytech Advisors SA Polytech Advisors SA Investment ManagersFinance Acts as an alternative investment manager	Directeur/Membre du Conseil	10/01/2012
DFB Pharmaceuticals LLC DFB Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products	Directeur/Membre du Conseil	-
VEXIM	Directeur/Membre du Conseil	-
░░░░░░░░░░ ░░	░░░░░░░░░	-

Voir l'expérience en détail de Jacques R. Essinger

Formation de Jacques R. Essinger

Expériences
Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Voir l'expérience en détail de Jacques R. Essinger

Relations

Relations au 1er degré

Entreprises liées au 1er degré

Homme

Femme

Administrateurs

Exécutifs

Voir le réseau personnel

Sociétés liées

Entreprise privées	13
Nuvaira, Inc. Nuvaira, Inc. Medical SpecialtiesHealth Technology Develops medical devices for treating lung diseases	Health Technology
École Polytechnique Fédérale de Lausanne École Polytechnique Fédérale de Lausanne Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
DFB Pharmaceuticals LLC DFB Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products	Health Technology
Genedata AG Genedata AG Packaged SoftwareTechnology Services Provides software solutions for biopharmaceutical R&D	Technology Services
Aravis AG Aravis AG Investment ManagersFinance Aravis is a hands-on investment partner. They work closely with their portfolio firms while providing capital and access to their international network of professionals. The firm's investment strategy targets early-stage firms active in biopharmaceutical, medical technology and biotechnology sectors in Europe, North America and Asia. They have a particular focus on cross-border deals and in firms operating in immunology, inflammation, oncology and CNS segments. They also invest in renewable energy businesses in Europe where they believe there are substantial growth opportunities. They concentrate on firms in the development phase which employ mature established energy production technologies, namely wind, hydroelectric or photovoltaic cells. Aravis has experience initiating, financing and structuring complex projects. The firm aims to diligently conduct scientific and technical analysis of potential projects prior to capital commitment. They look for firms which display optimal risk/return profiles. They closely monitor the quality of the science and actively continue with hands-on intervention in challenging situations, aiming to create value through deal structuring in parallel with careful entry valuations.	Finance
Symetis SA Symetis SA BiotechnologyHealth Technology Develops products for pediatric cardio-vascular applications	Health Technology
Endeavour Vision SA Endeavour Vision SA Investment ManagersFinance EV develops a long-term investment strategy with their entrepreneurs. Their investment objective is to grow firms and to create a market leader in a new field. They focus on developing businesses active in industries including information technology, biotech, medtech and cleantech. They concentrate on various stages such as early to expansion-stage as well as spin-offs and restarts. Their geographic focus is pan-European. Specifically, their technology-sector investments are concentrated in Norway, Sweden, Finland, UK, Ireland, Germany, Switzerland, France, Italy and Portugal. Beyond these countries, they also consider taking a co-lead or a syndicate role. For their life sciences investments, they primarily target Switzerland, France and Germany. Four key investment criteria they consider before investment are hyper-growth market potential, world-class technology, capital efficiency and ambitious management team. EV's preferred role is to be lead investor or possibly co-lead. They also consider being syndicate partner on some occasions. EV's investment horizon is generally 10 years, with that timeframe extended for firms in hyper-growth stage. On average, their investments typically take five years to mature. The majority of their exits are through a listing in one of the main markets while many of the VC-backed firms are acquired.	Finance
Diagnoplex SA Diagnoplex SA Medical SpecialtiesHealth Technology Develops molecular diagnostics for colon cancer	Health Technology
Vexim SA Vexim SA Miscellaneous Commercial ServicesCommercial Services Provides biotechnology research and development services	Commercial Services
Polytech Advisors SA Polytech Advisors SA Investment ManagersFinance Acts as an alternative investment manager	Finance
V-Wave Ltd. V-Wave Ltd. Medical SpecialtiesHealth Technology Develops treatment options for people living with heart failure and cardiovascular disease	Health Technology
Polares Medical SA Polares Medical SA Medical SpecialtiesHealth Technology Operates as a medical device company with a novel devices for treating mitral valve regurgitation	Health Technology
Polares Medical, Inc. Polares Medical, Inc. Part of Polares Medical SA, Polares Medical, Inc. is an American medical device company focused on developing a novel device to treat mitral valve regurgitation. The company is located in the US.